Glycosaminoglycan-Based CD44-Targeted Nanoparticles for Cancer Therapy: Biological Barriers and Barrier-Informed Design Strategies
- 1UPMC Hillman Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States
Abstract
Nanoparticle (NP)-based drug delivery has been explored to improve the therapeutic index of anticancer agents by enhancing tumor accumulation and reducing systemic toxicity. Among active targeting approaches, cluster of differentiation 44 (CD44) has attracted attention because of its overexpression in tumor cells and tumor-associated endothelial cells and its involvement in tumor progression and therapeutic resistance. Hyaluronic acid (HA) and other glycosaminoglycan (GAG)-based nanocarriers have been developed to exploit CD44-mediated tumor targeting and cellular uptake. However, the in vivo performance of CD44-targeted NPs remains variable because of barriers such as systemic clearance, heterogeneous tumor vasculature and stroma, limited receptor accessibility, competition with endogenous ligands, and inefficient intracellular trafficking or payload release. This Letter summarizes advances in CD44-targeted NP delivery, focusing on barriers at systemic, tumor tissue, and cellular levels. We discuss barrier-informed strategies to optimize ligand presentation, improve penetration, promote intracellular payload release, and highlight translational challenges and opportunities for CD44-targeted nanomedicines.
Related
- Mycogenic synthesis of copper oxide nanoparticles using response surface methodology and assessment of their biological potential
- Targeted delivery of celastrol and siRNA via macrophage biomimetic nanoparticles for doxorubicin-induced cardiomyopathy therapy
- Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles
- Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles
- From Design to Bedside: Brain-Targeted Engineered Nanoparticles and Predictive Modeling for Neurodegenerative Diseases Therapeutics
BibTeX
@article{chen2026glycosaminoglycanbased,
title = {{Glycosaminoglycan-Based CD44-Targeted Nanoparticles for Cancer Therapy: Biological Barriers and Barrier-Informed Design Strategies}},
author = {Shangyu Chen and Sheida Dabiri and Yichen Xu and Song Li},
journal = {Nano Letters},
year = {2026},
month = oct,
doi = {10.1021/acs.nanolett.6c02400},
url = {https://doi.org/10.1021/acs.nanolett.6c02400},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Glycosaminoglycan-Based CD44-Targeted Nanoparticles for Cancer Therapy: Biological Barriers and Barrier-Informed Design Strategies
AU - Shangyu Chen
AU - Sheida Dabiri
AU - Yichen Xu
AU - Song Li
PY - 2026
DA - 2026/10/04
JO - Nano Letters
DO - 10.1021/acs.nanolett.6c02400
UR - https://doi.org/10.1021/acs.nanolett.6c02400
AB - Nanoparticle (NP)-based drug delivery has been explored to improve the therapeutic index of anticancer agents by enhancing tumor accumulation and reducing systemic toxicity. Among active targeting approaches, cluster of differentiation 44 (CD44) has attracted attention because of its overexpression in tumor cells and tumor-associated endothelial cells and its involvement in tumor progression and therapeutic resistance. Hyaluronic acid (HA) and other glycosaminoglycan (GAG)-based nanocarriers have been developed to exploit CD44-mediated tumor targeting and cellular uptake. However, the in vivo performance of CD44-targeted NPs remains variable because of barriers such as systemic clearance, heterogeneous tumor vasculature and stroma, limited receptor accessibility, competition with endogenous ligands, and inefficient intracellular trafficking or payload release. This Letter summarizes advances in CD44-targeted NP delivery, focusing on barriers at systemic, tumor tissue, and cellular levels. We discuss barrier-informed strategies to optimize ligand presentation, improve penetration, promote intracellular payload release, and highlight translational challenges and opportunities for CD44-targeted nanomedicines.
SN - 1530-6984
SN - 1530-6992
ER -